FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4233217811> ?p ?o ?g. }

• W4233217811 abstract "Abstract Background: HER2-targeting agents have dramatically changed the therapeutic landscape of HER2+ advanced breast cancer (ABC). Within a short time frame, the rapid introduction of new therapeutics has led to the approval of pertuzumab combined with trastuzumab and a taxane in first-line, and trastuzumab emtansine (T-DM1) in second-line. Thereby, evidence of T-DM1 efficacy following trastuzumab/pertuzumab combination is limited, with data from some retrospective reports suggesting lower activity. The purpose of the present study is to investigate T-DM1 efficacy in pertuzumab-pretreated and pertuzumab naïve HER2 positive ABC patients. We also aimed to provide evidence on the exposure to different drugs sequences including pertuzumab and T-DM1 in HER2 positive cell lines. Methods: The biology of HER2 was investigated in vitro through sequential exposure of resistant HER2+breast cancer cell lines to trastuzumab, pertuzumab, and their combination. In vitro experiments were paralleled by the analysis of data from 555 HER2+ABC patients treated with T-DM1 and evaluation of T-DM1 efficacy in the 371 patients who received it in second line. Survival estimates were graphically displayed in Kaplan Meier curves, compared by log rank test and, when possibile, confirmed in multivariate models. Results: We herein show evidence of lower activity of T-DM1 in two HER2+ breast cancer cell lines resistant to trastuzumab+pertuzumab, as compared to trastuzumab-resistant cells. Lower T-DM1 efficacy was associated with a marked reduction of HER2 expression on the cell membrane and its nuclear translocation. HER2 downregulation at the membrane level was confirmed in biopsies of four trastuzumab/pertuzumab-pretreated patients. Among the 371 patients treated with second-line T-DM1, median overall survival (mOS) from diagnosis of advanced disease and median progression-free survival to second-line treatment (mPFS2) were 52 and 6 months in 177 patients who received trastuzumab/pertuzumab in first-line, and 74 and 10 months in 194 pertuzumab-naïve patients (p=0.0006 and 0.03 for OS and PFS2, respectively). Conclusions: Our data support the hypothesis that the addition of pertuzumab to trastuzumab reduces the amount of available plasma membrane HER2 receptor, limiting the binding of T-DM1 in cancer cells. This may help interpret the less favorable outcomes of second-line T-DM1 in trastuzumab/pertuzumab pre-treated patients compared to their pertuzumab-naïve counterpart." @default.
• W4233217811 created "2022-05-12" @default.
• W4233217811 creator A5001236278 @default.
• W4233217811 creator A5004091943 @default.
• W4233217811 creator A5004436634 @default.
• W4233217811 creator A5004830992 @default.
• W4233217811 creator A5005520202 @default.
• W4233217811 creator A5009199625 @default.
• W4233217811 creator A5010177673 @default.
• W4233217811 creator A5010531543 @default.
• W4233217811 creator A5011132933 @default.
• W4233217811 creator A5011753332 @default.
• W4233217811 creator A5012187098 @default.
• W4233217811 creator A5013519144 @default.
• W4233217811 creator A5015679343 @default.
• W4233217811 creator A5017866134 @default.
• W4233217811 creator A5018118709 @default.
• W4233217811 creator A5018301928 @default.
• W4233217811 creator A5019053015 @default.
• W4233217811 creator A5020078965 @default.
• W4233217811 creator A5020324515 @default.
• W4233217811 creator A5020344479 @default.
• W4233217811 creator A5020843675 @default.
• W4233217811 creator A5025268176 @default.
• W4233217811 creator A5027075905 @default.
• W4233217811 creator A5030465858 @default.
• W4233217811 creator A5034345931 @default.
• W4233217811 creator A5034522625 @default.
• W4233217811 creator A5035471408 @default.
• W4233217811 creator A5038529742 @default.
• W4233217811 creator A5038676900 @default.
• W4233217811 creator A5040783792 @default.
• W4233217811 creator A5041668420 @default.
• W4233217811 creator A5042989547 @default.
• W4233217811 creator A5048165179 @default.
• W4233217811 creator A5050187820 @default.
• W4233217811 creator A5052593572 @default.
• W4233217811 creator A5053974958 @default.
• W4233217811 creator A5054443196 @default.
• W4233217811 creator A5058082424 @default.
• W4233217811 creator A5059504916 @default.
• W4233217811 creator A5060183078 @default.
• W4233217811 creator A5060428508 @default.
• W4233217811 creator A5065261887 @default.
• W4233217811 creator A5065403219 @default.
• W4233217811 creator A5067282968 @default.
• W4233217811 creator A5067689545 @default.
• W4233217811 creator A5068721926 @default.
• W4233217811 creator A5072842070 @default.
• W4233217811 creator A5073559640 @default.
• W4233217811 creator A5076498258 @default.
• W4233217811 creator A5080721675 @default.
• W4233217811 creator A5085953932 @default.
• W4233217811 creator A5089164502 @default.
• W4233217811 creator A5091286114 @default.
• W4233217811 date "2020-12-23" @default.
• W4233217811 modified "2023-10-17" @default.
• W4233217811 title "Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade. The SePHER Study." @default.
• W4233217811 doi "https://doi.org/10.21203/rs.3.rs-71502/v2" @default.
• W4233217811 hasPublicationYear "2020" @default.
• W4233217811 type Work @default.
• W4233217811 citedByCount "0" @default.
• W4233217811 crossrefType "posted-content" @default.
• W4233217811 hasAuthorship W4233217811A5001236278 @default.
• W4233217811 hasAuthorship W4233217811A5004091943 @default.
• W4233217811 hasAuthorship W4233217811A5004436634 @default.
• W4233217811 hasAuthorship W4233217811A5004830992 @default.
• W4233217811 hasAuthorship W4233217811A5005520202 @default.
• W4233217811 hasAuthorship W4233217811A5009199625 @default.
• W4233217811 hasAuthorship W4233217811A5010177673 @default.
• W4233217811 hasAuthorship W4233217811A5010531543 @default.
• W4233217811 hasAuthorship W4233217811A5011132933 @default.
• W4233217811 hasAuthorship W4233217811A5011753332 @default.
• W4233217811 hasAuthorship W4233217811A5012187098 @default.
• W4233217811 hasAuthorship W4233217811A5013519144 @default.
• W4233217811 hasAuthorship W4233217811A5015679343 @default.
• W4233217811 hasAuthorship W4233217811A5017866134 @default.
• W4233217811 hasAuthorship W4233217811A5018118709 @default.
• W4233217811 hasAuthorship W4233217811A5018301928 @default.
• W4233217811 hasAuthorship W4233217811A5019053015 @default.
• W4233217811 hasAuthorship W4233217811A5020078965 @default.
• W4233217811 hasAuthorship W4233217811A5020324515 @default.
• W4233217811 hasAuthorship W4233217811A5020344479 @default.
• W4233217811 hasAuthorship W4233217811A5020843675 @default.
• W4233217811 hasAuthorship W4233217811A5025268176 @default.
• W4233217811 hasAuthorship W4233217811A5027075905 @default.
• W4233217811 hasAuthorship W4233217811A5030465858 @default.
• W4233217811 hasAuthorship W4233217811A5034345931 @default.
• W4233217811 hasAuthorship W4233217811A5034522625 @default.
• W4233217811 hasAuthorship W4233217811A5035471408 @default.
• W4233217811 hasAuthorship W4233217811A5038529742 @default.
• W4233217811 hasAuthorship W4233217811A5038676900 @default.
• W4233217811 hasAuthorship W4233217811A5040783792 @default.
• W4233217811 hasAuthorship W4233217811A5041668420 @default.
• W4233217811 hasAuthorship W4233217811A5042989547 @default.
• W4233217811 hasAuthorship W4233217811A5048165179 @default.
• W4233217811 hasAuthorship W4233217811A5050187820 @default.
• W4233217811 hasAuthorship W4233217811A5052593572 @default.
• W4233217811 hasAuthorship W4233217811A5053974958 @default.
• W4233217811 hasAuthorship W4233217811A5054443196 @default.

• next